Clinical trial
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin…
NCT00087568 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00087568 |
|---|---|
| Title | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin |
| Official title | An Open-label, Multicenter, Efficacy and Safety Study of Pegasys® Plus Ribavirin in Patients With Chronic HCV Infection Who Are Unable to Tolerate or Who Do Not Respond to 12 Weeks of Therapy With PEGIntron ® Plus Ribavirin |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Ribavirin, peginterferon alfa-2a [Pegasys] |
| Enrollment | 57 |
| Start date | Jan 1, 2003 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Jul 14, 2004 |
| Last update posted | Jun 8, 2016 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: